Reduzierte strahleninduzierte Hirnnekrose bei Patienten mit Nasopharynxkarzinom durch Bevacizumab-Monotherapie

Carl, Cedric Oliver; Henze, Marvin

doi:10.1007/s00066-019-01425-w

Cited by 4 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2007, Gonzalez et al 3 were pioneers in reporting the use of bevacizumab to treat radiation‐induced brain necrosis. In recent years, several studies have confirmed the efficacy of bevacizumab in the treatment of radiation‐induced brain necrosis 4–11 . A comprehensive meta‐analysis involving 12 studies showed that bevacizumab is effective in treating radiation‐induced brain edema, leading to improved clinical symptoms and superior outcomes in comparison to the corticosteroid treatment 12 .…”

Section: Introductionmentioning

confidence: 99%

“…In recent years, several studies have confirmed the efficacy of bevacizumab in the treatment of radiation‐induced brain necrosis. 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 A comprehensive meta‐analysis involving 12 studies showed that bevacizumab is effective in treating radiation‐induced brain edema, leading to improved clinical symptoms and superior outcomes in comparison to the corticosteroid treatment. 12 However, the majority of these studies were conducted with limited sample sizes, 13 , 14 , 15 leaving several questions unanswered.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy

Hua,

Gao,

Wang

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundThe aim of this study was to investigate the efficacy of bevacizumab (Bev) in reducing peritumoral brain edema (PTBE) after stereotactic radiotherapy (SRT) for lung cancer brain metastases.MethodsA retrospective analysis was conducted on 44 patients with lung cancer brain metastases (70 lesions) who were admitted to our oncology and Gamma Knife center from January 2020 to May 2022. All patients received intracranial SRT and had PTBE. Based on treatment with Bev, patients were categorized as SRT + Bev and SRT groups. Follow‐up head magnetic resonance imaging was performed to calculate PTBE and tumor volume changes. The edema index (EI) was used to assess the severity of PTBE. Additionally, the extent of tumor reduction and intracranial progression‐free survival (PFS) were compared between the two groups.ResultsThe SRT + Bev group showed a statistically significant difference in EI values before and after radiotherapy (p = 0.0115), with lower values observed after treatment, but there was no difference in the SRT group (p = 0.4008). There was a difference in the distribution of EI grades in the SRT + Bev group (p = 0.0186), with an increased proportion of patients at grades 1–2 after radiotherapy, while there was no difference in the SRT group (p > 0.9999). Both groups demonstrated a significant reduction in tumor volume after radiotherapy (p < 0.05), but there was no difference in tumor volume changes between the two groups (p = 0.4089). There was no difference in intracranial PFS between the two groups (p = 0.1541).ConclusionBevacizumab significantly reduces the severity of PTBE after radiotherapy for lung cancer. However, its impact on tumor volume reduction and intracranial PFS does not reach statistical significance.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy

Hua,

Gao,

Wang

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…Since then, an increasing number of retrospective and prospective studies have illustrated the effectiveness of IVBEV in treating CRN. Most research centers have used dosages of 5 mg/kg every 2 weeks, 7.5 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks, with few using doses of 2.5 mg/kg every 2 weeks, 15 mg/kg every 3 weeks, or 4 weeks 12–22 . Two prospective studies conducted in China have successively demonstrated that IVBEV (5 mg/kg every 2 weeks) is superior to corticosteroids in treating CRN, and that ultra‐low‐dose IVBEV (1 mg/kg every 3 weeks) remains efficacious 23,24 .…”

Section: Introductionmentioning

confidence: 99%

“…Most research centers have used dosages of 5 mg/kg every 2 weeks, 7.5 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks, with few using doses of 2.5 mg/kg every 2 weeks, 15 mg/kg every 3 weeks, or 4 weeks. 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 Two prospective studies conducted in China have successively demonstrated that IVBEV (5 mg/kg every 2 weeks) is superior to corticosteroids in treating CRN, and that ultra‐low‐dose IVBEV (1 mg/kg every 3 weeks) remains efficacious. 23 , 24 Despite the therapeutic effects of different doses of IVBEV for CRN demonstrated in previous studies, the risk of treatment‐related AEs appears to increase with dose escalation, thus increasing the financial burden for patients.…”

Section: Introductionmentioning

confidence: 99%

Can low‐dose intravenous bevacizumab be as effective as high‐dose bevacizumab for cerebral radiation necrosis?

Gao,

Wang,

Wang

et al. 2023

Cancer Science

View full text Add to dashboard Cite

Although intravenous bevacizumab (IVBEV) is the most promising treatment for cerebral radiation necrosis (CRN), there is no conclusion on the optimal dosage. Our retrospective study aimed to compare the efficacy and safety of high‐dose with low‐dose IVBEV in treating CRN associated with radiotherapy for brain metastases (BMs). This paper describes 75 patients who were diagnosed with CRN secondary to radiotherapy for BMs, treated with low‐dose or high‐dose IVBEV and followed up for a minimum of 6 months. The clinical data collected for this study include changes in brain MRI, clinical symptoms, and corticosteroid usage before, during, and after IVBEV treatment. At the 3‐month mark following administration of IVBEV, a comparison of two groups revealed that the median percentage decreases in CRN volume on T2‐weighted fluid‐attenuated inversion recovery and T1‐weighted gadolinium contrast‐enhanced image (T1CE), as well as the signal ratio reduction on T1CE, were 65.8% versus 64.8% (p = 0.860), 41.2% versus 51.9% (p = 0.396), and 37.4% versus 35.1% (p = 0.271), respectively. Similarly, at 6 months post‐IVBEV, the median percentage reductions of the aforementioned parameters were 59.5% versus 62.0% (p = 0.757), 39.1% versus 31.3% (p = 0.851), and 35.4% versus 28.2% (p = 0.083), respectively. Notably, the incidence of grade ≥3 adverse events was higher in the high‐dose group (n = 4, 9.8%) than in the low‐dose group (n = 0). Among patients with CRN secondary to radiotherapy for BMs, the administration of high‐dose IVBEV did not demonstrate superiority over low‐dose IVBEV. Moreover, the use of high‐dose IVBEV was associated with a higher incidence of grade ≥3 adverse events compared with low‐dose IVBEV.

show abstract

“…Studies have found that the Nerve growth factor (NGF) and Shenqi Fuzheng Injection (SFI) can alleviate RBI [7,8]. Moreover, numerous studies have shown that Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, can reduce vascular permeability, normalize the blood-brain barrier, and reduce vasogenic brain edema, thereby effectively inhibiting the progression of RBI [9][10][11][12][13]. However, the anti-VEGFR antibody anlotinib has not attracted attention.…”

mentioning

confidence: 99%

Mitigation of Acute Radiation-Induced Brain Injury by Anlotinib: A Meaningful Study

Li,

Feng,

et al. 2023

Neurodegener Dis Cur Res

View full text Add to dashboard Cite

Reduzierte strahleninduzierte Hirnnekrose bei Patienten mit Nasopharynxkarzinom durch Bevacizumab-Monotherapie

Cited by 4 publications

References 13 publications

Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy

Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy

Can low‐dose intravenous bevacizumab be as effective as high‐dose bevacizumab for cerebral radiation necrosis?

Mitigation of Acute Radiation-Induced Brain Injury by Anlotinib: A Meaningful Study

Contact Info

Product

Resources

About